Programmed Death Ligand-1 Expression Is Associated With Poor Disease Free Survival in Salivary Gland Carcinomas
Programmed Death Ligand-1 Expression Is Associated With Poor Disease Free Survival in Salivary Gland Carcinomas
复制标题
DOI：
10.1002/jso.24266
复制
发表时间：
2016-07-01
影响因子：
2.5
通讯作者：
Fujii, Satoshi
中科院分区：
文献类型：
--
作者：
Mukaigawa, Takashi;Hayashi, Ryuichi;Fujii, Satoshi
背景和目的：免疫检查点配体程序性死亡配体-1 （PD-L1）在多种癌症中表达，并允许癌细胞逃避免疫系统。PD-L1表达与抗程序性死亡1 (PD-1)/PD-L1药物的反应有关。本研究旨在阐明PD-L1表达与涎腺癌（SGCs）临床病理因素的关系，并探讨其临床意义。方法：利用219例手术切除的SGC标本组织芯片，通过免疫组化分析检测PD-L1的表达。所有病例均有详细的临床病理因素，包括患者预后。结果：一个PD-L1在超过1%的整个癌细胞中完全膜性表达的病例通过ROC分析被认为是阳性的。共有50例（22.8%）患者在SGC细胞中表达PD-L1。PD-L1阳性表达与无病生存期差（P < 0.001）和总生存期差（P < 0.001）显著相关。多因素分析显示，PD-L1阳性表达是无病生存差的独立预测因素之一（风险比= 2.287,95%可信区间= 1.24-4.15;P = 0.008）。结论：PD-L1阳性表达与SGCs无病生存期差显著相关，提示针对PD-1/PD-L1的抗体治疗可能在SGCs中有潜在的应用前景。(C) 2016 Wiley期刊公司
Background and Objectives: The immune checkpoint ligand programmed death ligand-1 (PD-L1) is expressed in various carcinomas and allows carcinoma cells to elude the immune system. PD-L1 expression is associated with the response to anti-programmed death 1 (PD-1)/PD-L1 drugs. This study aimed to clarify the relationship between PD-L1 expression and clinicopathological factors of salivary gland carcinomas (SGCs) and identify its clinical significance.Methods: PD-L1 expression was examined by immunohistochemical analysis using a tissue microarray comprised of 219 surgically resected SGC specimens. Detailed clinicopathological factors, including patient outcome, were available for all cases.Results: A case showing complete membranous expression of PD-L1 in more than 1% of whole carcinoma cells was considered positive by ROC analysis. A total of 50 (22.8%) patients showed PD-L1 expression in SGC cells. Positive PD-L1 expression was significantly associated with poor disease free survival (P < 0.001) and overall survival (P < 0.001). Multivariate analysis revealed that positive PD-L1 expression was one of the independent predictors for poor disease free survival (hazard ratio = 2.287, 95% confidence interval = 1.24-4.15; P = 0.008).Conclusions: Positive PD-L1 expression was significantly associated with poor disease free survival of SGCs, suggesting that antibody therapies targeting PD-1/PD-L1 may have potential application in SGCs. (C) 2016 Wiley Periodicals, Inc.